Janssen’s Erleada (apalutamide) Receives Health Canada’s Approval for Metastatic Castration-Sensitive Prostate Cancer

 Janssen’s Erleada (apalutamide) Receives Health Canada’s Approval for Metastatic Castration-Sensitive Prostate Cancer

Janssen’s Erleada (apalutamide) Receives Health Canada’s Approval for Metastatic Castration-Sensitive Prostate Cancer

Shots:

  • The approval is based on P-III TITAN study assessing Erleada (240mg) + ADT vs PBO + ADT in 1052 patients in a ratio (1:1) with mCSPC across 23 countries including North America, Latin America, South America, EU and the Asia Pacific
  • The P-III TITAN study resulted in achieving statistical significance in dual 1EPs of OS & rPFS i.e, 33% reduction in risk of death & 52% reduction in rPFS, OS @2yrs. (82% vs 74%)
  • Erleada (PO, qd) is an androgen receptor (AR) inhibitor, indicated to treat patients with nmCRPC & mCSPC and has received Health Canada’s approval for nmCRPC on Jul 03, 2018

Click here to­ read full press release/ article | Ref: Newswire Canada | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post